{"id":"NCT02077192","sponsor":"Rigel Pharmaceuticals","briefTitle":"Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)","officialTitle":"A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10","primaryCompletion":"2020-06-02","completion":"2020-06-02","firstPosted":"2014-03-04","resultsPosted":"2023-12-11","lastUpdate":"2023-12-11"},"enrollment":123,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Immune Thrombocytopenic Purpura"],"interventions":[{"type":"DRUG","name":"Fostamatinib Disodium","otherNames":["R935788","R788","Fostamatinib"]}],"arms":[{"label":"Fostamatinib Disodium","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP","primaryOutcome":{"measure":"Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/ÂµL Within 12 Weeks of Beginning Treatment up to 12 Months (Fostamatinib in 047/048 or 049):Version 1","timeFrame":"Up to 12 months","effectByArm":[{"arm":"Fostamatinib Disodium","deltaMin":15.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":55,"countries":["United States","Australia","Austria","Bulgaria","Canada","Czechia","Denmark","Hungary","Italy","Netherlands","Norway","Poland","Romania","Spain","United Kingdom"]},"refs":{"pmids":["33995988"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":123},"commonTop":["Diarrhoea","Hypertension","Epistaxis","Petechiae","Headache"]}}